Federal law would override state medicine restrictions, opening door to litigation

What it does

This bill creates a federal statutory right for individuals to obtain FDA-approved medicines and for healthcare providers to prescribe them, free from state or federal restrictions that single out or impede access to those medicines. It allows individuals and providers to sue in federal court to block any law, rule, or requirement that limits FDA-approved medicines, unless the government proves by clear and convincing evidence that the restriction significantly advances medicine access and has no less restrictive alternative.

Why we flagged it

The bill's core mechanism is a federal statutory right to obtain and prescribe FDA-approved medicines, coupled with preemption of state law and a private right of action. It is framed as a patient/provider protection but functions as a broad state-law override with significant implications for medical licensing, insurance coverage, and professional standards.

What the text implies

• The bill's definition of 'limitation or requirement' that 'singles out' or 'impedes' FDA-approved medicines is extremely broad and may capture state insurance coverage decisions, professional licensing standards, prescribing protocols, and pharmacy benefit manager restrictions—creating federal liability for routine medical regulation.
• Section 5(c) carves out health insurance coverage decisions, but the carve-out is narrow and may not protect state Medicaid programs, workers' compensation, or public employee health plans from challenge under the bill's private right of action.
• The 'clear and convincing evidence' standard in Section 4(c) places a heavy burden on government defendants to justify any restriction, potentially making it difficult for states to enforce evidence-based prescribing limits, controlled-substance regulations, or safety protocols.
• Section 6(c) defines 'any individual who, by operation of a provision of Federal or State law, is permitted to implement or enforce' a restriction as a 'government official,' potentially exposing private actors (pharmacy benefit managers, insurance companies, hospital credentialing committees) to federal suit if they restrict medicine access.
• The bill's preemption language in Section 5(a)(1) applies to 'law of the Federal Government and each State' and 'whether adopted before or after the date of enactment,' potentially invalidating existing state medical practice acts, pharmacy regulations, and controlled-substance laws that restrict certain FDA-approved medicines.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain a federal right to challenge state restrictions on FDA-approved medicines and access to federal courts with attorney's fees, which may expand access to certain treatments. However, the bill's broad language and low evidentiary bar for plaintiffs (clear and convincing evidence required only of defendants) may also shield medicines from legitimate state safety oversight, professional licensing standards, or coverage decisions—potentially creating liability for states enforcing eviden

Who stands to gain

• pharmaceutical manufacturers (expanded market access, reduced state-level restrictions)
• healthcare providers (reduced liability for prescribing, expanded prescribing authority)
• pharmacy benefit managers and insurers (if they can defend restrictions as advancing access)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), State governments, Healthcare providers (physicians, nurses, pharmacists, nurse practitioners, physician assistants), Patients/individuals, Attorney General (U.S.), Federal district courts, Religious Freedom Restoration Act of 1993, Social Security Act (Medicaid), Public Health Service Act

Where it stands

29 cosponsors: 29 Democrats.

• Jul 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 17, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.